Hepatitis C virus (HCV) is the second most common cause of viral hepatitis worldwide. HCV genotype is the strongest predictive factor for sustained virological response (SVR). The patients with different HCV genotypes act differently in response to alpha interferon therapy, thus, the patient genotype plays vital role in treatment outcome. The aim of the present study was to assess molecular epidemiology of HCV genotypes and subtypes circulating in Hyderabad, Sindh. A cross sectional study was conducted for a period of six months from July2015 to December 2015. A total of 577 samples of HCV positive patients were collected for analysis of HCV genotypes and subtypes using Real-time PCR Assay. Out of 577 cases 57.54% (n=332) were male and 42.46% (n=245) were females. Age groups between 21 and 60 years comprised 90.47 % (n=522) of the patients. HCV 3 genotype was most frequent genotype infecting 489 (84.75%) of the patients. The second most common variety was untypeable 9.36% (n=54). A little number of patients yielded mixed variety of genotypes. The prevalence of other genotypes as follows: Genotype 1(0.52%), 1, 1a (0.87%), 1, 1b (2.43%), 1b (0.17%), 2 (0.69%), 3, 4 (0.87%), 4 (0.35%). Genotypes 5 and 6 were not identified in any patient enrolled in this study. In summary, HCV genotype 3 was the most prevalent at Hyderabad, Sindh. Despite the availability of antiviral therapy, apparent increase in HCV 3 genotype burden seems alarming and warrants urgent measures to prevent the spread of HCV infection.
Introduction Viral hepatitis is major public health concern across the world. Out of six main viruses, HCV has been reported to causes a prolonged chronic type of hepatitis infection in susceptible patients [1] . HCV is an enveloped virus which was first reported in 1989 [2] . HCV possesses single stranded nonsegmented, linear, ribonucleic acid (RNA) enclosed in nucleocapsid, surrounded by envelope and appears icosahederal in shape [3] . HCV Hyderabad from six months from July 2015 to June 2015. HCV RNA positive patients of more than 16 years in age and chronically infected with HCV, were enrolled in the study. A total of 577 blood samples were collected from HCV patients for determining HCV genotypes. Collection of blood sample and serum separation Using sterile syringe, 5 ml of blood was collected from each patient by veinpuncture. Blood samples were immediately added to BD vacutainer serum separation tubes and processed for serum separation as per manufacturer's guidelines. Briefly, the gel tubes were inverted five times, and allowed to stand 30 minutes for clotting, and then centrifuged at 3000 rpm for 10 minutes. The gel in tubes forms a physical barrier between serum and blood cells during centrifugation. After centrifugation separated serum obtained and the sample was ready to be further processed. Samples were either used immediately or stored at -20ºC for future use HCV genotyping assay Genotyping analysis was carried out using reverse transcription-polymerase chain reaction (RT-PCR) using Abbott Real Time HCV Genotype assay kit as per manufacturer's guidelines (Abbot, USA). The genotyping kit uses genotype-specific fluorescent-labeled oligonucleotide probes to detect six major genotypes including genotype1, genotype 2, genotype 3, genotype 4, genotype 5, and genotype 6, as well as two subtypes such as1a and 1b.The primers target the 5'UTR region of HCV genome for the classification of genotypes 1 through 6, and the NS5B region to determine the subtype 1a and 1b of HCV (Abbott Real Time HCV Genotype II).
Results and discussion
The current study has investigated the types and frequency of HCV genotypes in patients from Hyderabad, Sindh. The data revealed that out of 577 HCV positive samples subjected for genotyping, 332 (57.54%) were male and 245 (42.46%) were females. Females were slightly less in number than the male patients studied in the present study. Moreover, the genotyping data demonstrated that HCV genotype 3 was the most frequent genotype infecting 84.75% (n=489) of the total HCV patients. The second most common variety was un-typeable with 9.36% (n=54) samples. A little number of patients yielded mixed variety of genotypes. The prevalence of other genotypes included Genotype 1(0.52%), 1, 1a (0.87%), 1, 1b (2.43%), 1b (0.17%), 2 (0.69%), 3, 4 (0.87%) and 4 (0.35%). Genotypes 5 and 6 were not identified in any patient enrolled this study. Genotyping of samples yielded 8 different genotypes and subtypes including (1,1a), (1,1b) , (1b), (2), (3), and (3, 4) ( Table 1) . However, HCV genotypes 1a, 5, and 6 were not detected among patients studied. Genotype 3 was the most prevalent one detected in 84.75% of patients, followed by untypable genotype (9.36%) and then genotype 1b, 1a and mixed genotypes (3 & 4) . Genotype 1 was the least prevalent and was detected in only in 0.52% patients. The studied patients were categorized in three different age groups and then prevalence of age associated HCV genotypes among male and female patients was determined (Table 2 & 3). A slight difference in gender-wise distribution was found in genotypes. Genotype 3 was the most prevalent in both male and female patients. Seven genotypes were common in both genders; however, genotype 4 was only detected in males but not in females in the present study. HCV 3 was most prevalent genotype followed by (1, 1b), (1 1a), (3, 4) , (2), (1), and (4). The present study has also demonstrated mixed HCV genotypes; however, only one pattern of mixed genotypes (3, 4) with a very low prevalence was noticed. The second most common type was unidentified/untypeable genotype. The pattern of genotype distributions in male and females revealed that although HCV genotype 3 was the most common genotype in both genders, no substantial difference in the distribution of genotypes between two genders was observed. The findings of present study are in agreement with previous studies from other parts of Pakistan and especially Karachi. Other genotypes and subtypes, although were less frequent, included 1, 1a 1b, 2, 3, and 4. Genotype 4 was only detected in males not in females (Table 3) . Despite of availability of antiviral therapy, apparent increasing pattern of HCV 3 patient's burden especially Hyderabad is alarming and needs special measures to prevent the transmission of infection. Periodical investigations of HCV genotypes are needed to monitor distribution patterns of genotypes to facilitate treatment options and preventive strategies. 
